Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in biochemically recurrent prostate cancer
NCT04019964Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Jan 2020
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in prostate cancer (PCa), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Percentage of Participants With PSA50 Response. Started Jan 2020; status: completed.
02
Drugs
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04019964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04019964.